This tumor had mutations in TP53 and the epigenetic modifier EP300. Strikingly, this did not demonstrate LOH for CYLD. The BCAC-LG (PD40545a) tumor demonstrated a frameshift mutation in BCOR. The atypical spiradenocarcinoma (PD40540a) did not show any changes apart from CYLD LOH. This evidence concerns the gene EP300 and neoplasm.